molecule library

Offers 910 small molecules that enhance gene editing efficiency, suitable for high-throughput screening (HTS) and high-content screening (HCS);

A unique collection of 2850 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

120 well-chosen unique AMPK-targeted small molecules;

A unique collection of 1120 compounds targeting NF-κB signaling for high throughput screening and high content screening;

A unique collection of 1440 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 300 calcium channel blockers and agonists for high throughput and high content screening;

A unique collection of 2405 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 924 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;

A unique collection of 2975 approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 3660 drugs with anti-cancer activity or potential anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 718 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A collection of 19170 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 1960 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 950 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 693 rare natural products, which can be used for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

The library consists of 3745 members belonging 22 scaffolds (average 180 compounds per scaffold).

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

A unique collection of 680 EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A collection of 264 globally withdrawn small-molecule drugs, suitable for high-throughput screening (HTS) and high-content screening (HCS);

A collection of 230 small-molecule compounds approved by the U.S. FDA for veterinary use, suitable for high-throughput screening (HTS) and high-content screening (HCS)